Subscribe to this collection to receive daily e-mail notification of new additions

Issue Date	Title	Author(s)
2013-01	Anxiolytic-like effect of linezolid in experimental mouse models of anxiety	Mahesh, R.
2013-08	Antidepressant-like activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5-HT3 receptor antagonist in behaviour based rodent models: Evidence for the involvement of serotonergic system	Mahesh, R.
2014-05	Effect of a Selective Cyclooxygenase Type 2 Inhibitor Celecoxib on Depression Associated with Obesity in Mice: An Approach Using Behavioral Tests	Mahesh, R.
2014-11	Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression	Mahesh, R.
2017-10	A novel class of Plasmodial ClpP protease inhibitors as potential antimalarial agents	Mahesh, R.
2004	Pharmacophore Based Synthesis of 3-Chloroquinoxaline-2-carboxamides as Serotonin3 (5-HT3) Receptor Antagonist	Mahesh, R.
2012-08	Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor—an approach using rodent behavioral antidepressant tests battery	Mahesh, R.
2010-11	Design, synthesis and structure–activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression	Mahesh, R.
2014-07	Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models	Mahesh, R.
2015-01	QCM-4, a 5-HT3 receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice	Mahesh, R.
2006-05	Synthesis and biological evaluation of a novel structural type of serotonin 5-HT3 receptor antagonists	Mahesh, R.
2014-06	Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests	Mahesh, R.
2014-08	Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy	Mahesh, R.
2015-09	Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission	Mahesh, R.
2015-05	Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system	Mahesh, R.
2014-03	Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice	Mahesh, R.
2015-10	Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention	Mahesh, R.
2016-06	Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice	Mahesh, R.
2004-10	Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists	Mahesh, R.
2007-12	Potential antidepressants: Pharmacology of 2-(4-methyl piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile in rodent behavioural models	Mahesh, R.